Survival Outcomes
11
2
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (11)
Response Times in Danish Emergency Medical Services
ML Decision Model for G-NEC Adjuvant Therapy
Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Prognosis of Low-grade Endometrial Stromal Sarcoma
Donafenib for Recurrent Cervical Cancer
Chromosomal Instability in Ovarian Cancer
A Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients